FDA approves oncology drug that targets genetic driver of a tumor

Alia Paavola - Print  | 

The FDA has approved Rozlytrek, Roche's personalized cancer treatment that targets tumors with a specific genetic mutation.

The treatment targets certain types of solid tumors that show rare genetic defects called NTRK gene fusions. 

The treatment works regardless of where the tumor started in the body, according to a news release. 

This is the third oncology drug that targets a key genetic driver of cancer rather than a specific type of tumor. 

More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.